You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 8,647,840


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,647,840
Title:In vivo unnatural amino acid expression in the methylotrophic yeast Pichia pastoris
Abstract: The invention provides orthogonal translation systems for the production of polypeptides comprising unnatural amino acids in methylotrophic yeast such as Pichia pastoris. Methods for producing polypeptides comprising unnatural amino acids in methylotrophic yeast such as Pichia pastoris are also provided.
Inventor(s): Young; Travis (San Diego, CA), Schultz; Peter G. (La Jolla, CA)
Assignee: The Scripps Research Institute (La Jolla, CA)
Application Number:12/734,995
Patent Claims:1. A method for producing, in a methylotrophic yeast cell, a polypeptide of interest comprising an unnatural amino acid at a selected position, the method comprising: a) providing a methylotrophic yeast cell comprising: i) an unnatural amino acid; ii) an orthogonal aminoacyl-tRNA synthetase (O-RS) derived from Escherichia coli, wherein providing an O-RS comprises providing an O-RS polynucleotide under the transcriptional control of a FLD1 promoter; and, iii) an orthogonal tRNA (O-tRNA) derived from Escherichia coli, wherein the O-RS and the O-tRNA are encoded in a cassette on a single plasmid and stably integrated into the cell genome at an ARG4 gene, and wherein the O-RS preferentially aminoacylates the O-tRNA with the unnatural amino acid in the methylotrophic yeast cell; and, iv) a nucleic acid of interest encoding a polypeptide of interest, wherein the nucleic acid of interest comprises at least one selector codon that is recognized by the O-tRNA, and wherein the nucleic acid of interest is encoded in a cassette on a second plasmid and stably integrated into the cell genome; and, b) incorporating the unnatural amino acid at a selected position in the nucleic acid of interest during translation of the polypeptide of interest in response to a selector codon, thereby producing the polypeptide of interest comprising the unnatural amino acid at the selected position.

2. The method of claim 1, wherein the cell comprises O-tRNA that is an amber suppressor tRNA, an ochre suppressor tRNA, an opal suppressor tRNA, or a tRNA that recognizes a four base codon, a rare codon, or a non-coding codon, which O-tRNA is encoded by an O-tRNA polynucleotide under the transcriptional control of a high-level constitutive promoter.

3. The method of claim 2, wherein the high-level constitutive promoter comprises a PGK1 promoter.

4. The method of claim 1, wherein providing the nucleic acid of interest encoding the polypeptide comprises providing a nucleic acid encoding an HSA, a human neutral endopeptidase (NEP), an antibody, an Fab, an Fv, an alpha-1 antitrypsin, an angiostatin, an antihemolytic factor, an apolipoprotein, an apoprotein, an atrial natriuretic factor, an atrial natriuretic polypeptide, an atrial peptide, a C--X--C chemokine, a T39765, a NAP-2, an ENA-78, a gro-a, a gro-b, a gro-c, an IP-10, a GCP-2, a NAP-4, an SDF-1, a PF4, a MIG, a calcitonin, a c-kit ligand, a cytokine, a CC chemokine, a monocyte chemoattractant protein-1, a monocyte chemoattractant protein-2, a monocyte chemoattractant protein-3, a monocyte inflammatory protein-1 alpha, a monocyte inflammatory protein-1 beta, a RANTES, an 1309, an R83915, an R91733, an HCC1, a T58847, a D31065, a T64262, a CD40, a CD40 ligand, a c-kit ligand, a collagen, a colony stimulating factor (CSF), a complement factor 5a, a complement inhibitor, a complement receptor 1, a cytokine, an epithelial neutrophil activating peptide-78, a GRO', a MGSA, a GRO.beta., a GRO.gamma., a MIP1-.alpha., a MIP1-.beta., an MCP-1, a human epidermal growth factor (hEGF), an epithelial neutrophil activating peptide, an erythropoietin (EPO), an exfoliating toxin, a factor IX, a factor VII, a factor VIII, a factor X, a fibroblast growth factor (FGF), an FGF21, a fibrinogen, a fibronectin, a G-CSF, a GM-CSF, a human glucocerebrosidase, a gonadotropin variants, a growth factor, a growth factor receptor, a hedgehog protein, a hemoglobin, a hepatocyte growth factor (HGF), a Hirudin, a human serum albumin (HSA), an ICAM-1, an ICAM-1 receptor, an LFA-1, an LFA-1 receptor, a human insulin, a human insulin-like growth factor (hIGF), an hIGF-I, an hIGF-II, a human interferon, an IFN-.alpha., an IFN-.beta., an IFN-.gamma., an interleukin, an IL-1, an IL-2, an IL-3, an IL-4, an IL-5, an IL-6, an IL-7, an IL-8, an IL-9, an IL-10, an IL-11, an IL-12, a keratinocyte growth factor (KGF), a lactoferrin, a leukemia inhibitory factor, a luciferase, a neurturin, a neutrophil inhibitory factor (NIF), a human oncostatin M (OSM), an osteogenic protein, an oncogene product, a parathyroid hormone, a PD-ECSF, a PDGF, a peptide hormone, a human growth hormone (hGH), a pleiotropin, a protein A, a protein G, a pyrogenic exotoxin A, a pyrogenic exotoxin B, a pyrogenic exotoxin C, a relaxin, a renin, an SCF/c-kit, a soluble complement receptor I, a soluble I-CAM 1, a soluble interleukin receptor, a soluble TNF receptor, a somatomedin, a somatostatin, a somatotropin, a streptokinase, a superantigen, a staphylococcal enterotoxin, an SEA, an SEB, an SEC1, an SEC2, an SEC3, an SED, an SEE, a steroid hormone receptor, a superoxide dismutase, a toxic shock syndrome toxin, a thymosin alpha 1, a tissue plasminogen activator, a tumor growth factor (TGF), a TGF-.alpha., a TGF-.beta., a human tumor necrosis factor (hTNF), a human tumor necrosis factor alpha, a human tumor necrosis factor beta, a human tumor necrosis factor receptor (TNFR), a VLA-4 protein, a VCAM-1 protein, a human vascular endothelial growth factor (hVEGEF), hVEGF165, a Urokinase, a Mos, a Ras, a Raf, a Met, a p53, a Tat, a Fos, a Myc, a Jun, a Myb, a Rel, an estrogen receptor, a progesterone receptor, a testosterone receptor, an aldosterone receptor, an LDL receptor, an inflammatory molecule, a signal transduction molecule, a transcriptional activator, a transcriptional suppressor, a hyalurin, a CD44, a corticosterone, a human thyroid peroxidase (hTPO), a tetanus toxin fragment C, a bovine pancreatic trypsin inhibitor (BPTI), a human amyloid precursor protein (APP), a human antithrombin III, a BP320 antigen, a human caspase-3, a hepatitis B surface antigen, a human sex steroid-binding protein (hSBP), a human endostatin, or a gp120.

5. The method of claim 1, wherein the nucleic acid of interest is under the transcriptional control of a promoter.

6. The method of claim 5, wherein integrating the nucleic acid into the genome comprises integrating the nucleic acid into the genome in a single copy.

7. The method of claim 6, wherein integrating the nucleic acid into the genome comprises integrating the nucleic acid at a locus encoding an AOX1 gene, ADE1 gene, a HIS4 gene, a URA3 gene, an ARG4 gene, an AOX2 gene, or a MET2 gene.

8. The method of claim 5, wherein providing the nucleic acid comprises integrating the nucleic acid into the genome in multiple copies.

9. The method of claim 8, wherein integrating the nucleic acid into the genome comprises integrating the nucleic acid at a locus 5' of AOX1.

10. The method of claim 5, wherein the promoter controlling the nucleic acid of interest is an inducible promoter.

11. The method of claim 10, wherein the inducible promoter comprises an AOX1 promoter, an AOX2 promoter, an ICL1 promoter, or an FLD1 promoter.

12. The method of claim 5, wherein the promoter controlling the nucleic acid of interest is a constitutive promoter.

13. The method of claim 12, wherein the constitutive promoter is a YPT1 promoter, or a GAP promoter.

14. The method of claim 1, wherein providing a methylotrophic yeast cell comprises providing a Candida cell, a Hansenula cell, a Pichia cell, or a Torulopsis cell.

15. The method of claim 1, wherein providing a methylotrophic yeast cell comprises providing a Pichia pastoris cell.

16. The method of claim 1, wherein producing a polypeptide comprising an unnatural amino acid at a selected position comprises culturing an appropriately prepared methylotrophic yeast cell in a 1:9 ratio of buffered complex methanol media (BMMY):buffered minimal methanol (BMM) and growing the culture in a shake flask to induce expression of the polypeptide.

17. The method of claim 16, wherein culturing an appropriately prepared methylotrophic yeast cell comprises culturing a Candida cell, a Hansenula cell, a Pichia cell, or a Torulopsis cell.

18. The method of claim 16, wherein culturing an appropriately prepared methylotrophic yeast cell comprises culturing a Pichia pastoris cell.

19. The method of claim 17, wherein producing a polypeptide comprising an unnatural amino acid at a selected position comprises growing the culture until it reaches the consistency of a paste.

20. The method of claim 1, wherein the produced polypeptide is sulfated.

21. The method of claim 1, wherein the produced polypeptide is glycosylated.

22. The method of claim 1, wherein the produced polypeptide comprises disulfide bonds.

23. The method of claim 1, wherein the produced polypeptide is expressed from said cells at a concentration of up to 10 mg/L.

24. The method of claim 1, wherein producing a polypeptide comprising an unnatural amino acid at a selected position comprises: a) inoculating YPD medium with a colony of an appropriate Pichia pastoris strain to produce a first culture; b) growing the first culture to near saturation in a shake flask, wherein the shake flask is shaken at a rate of 280 rpm at a temperature between 29.degree. C. and 30.degree. C.; c) inoculating 1 liter of buffered media glycerol yeast extract (BMGY) with the first culture to produce a second culture; d) growing the second culture to an OD600 of 8.0; e) centrifuging the second culture at 1500.times.g for 5 minutes to form a pellet; f) resuspending the pellet in 200 ml of a 1:9 ratio of buffered complex methanol media (BMMY):buffered minimal methanol (BMM) to produce a third culture; and, g) adding methanol to the third culture to a final concentration of 0.5% every 24 hours thereafter for 120-144 hours to maintain induction of expression of the polypeptide.

Details for Patent 8,647,840

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Eli Lilly And Company HUMULIN R U-100 insulin human Injection 018780 10/28/1982 ⤷  Try a Trial 2027-12-11
Eli Lilly And Company HUMULIN R U-500 insulin human Injection 018780 12/29/2015 ⤷  Try a Trial 2027-12-11
Eli Lilly And Company HUMULIN R U-100 insulin human Injection 018780 08/06/1998 ⤷  Try a Trial 2027-12-11
Eli Lilly And Company HUMULIN R U-500 insulin human Injection 018780 03/31/1994 ⤷  Try a Trial 2027-12-11
Eli Lilly And Company HUMULIN R U-100 insulin human Injection 018780 05/25/2018 ⤷  Try a Trial 2027-12-11
Microbix Biosystems Inc. KINLYTIC urokinase For Injection 021846 01/16/1978 ⤷  Try a Trial 2027-12-11
Nps Pharmaceuticals, Inc. NATPARA parathyroid hormone For Injection 125511 01/23/2015 ⤷  Try a Trial 2027-12-11
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.